Vascular Regenerative Cell Flux in Diabetes: Mechanistic and Clinical Implications

Type 2 diabetes mellitus (T2DM) disrupts the quantity, phenotype, and function of circulating vascular regenerative (VR) progenitor cells that are critical to vessel repair. These impairments include reduced progenitor clonogenicity, mobilization and homing to areas of ischemia, and imbalances in secretory function, collectively contributing to poor vascular healing and complications such as peripheral artery disease, critical limb ischemia, and cardiovascular disease. Despite growing recognition of VR cell exhaustion, regenerative strategies remain hindered by imprecise cell phenotyping, underused functional assays, and insufficient integration of disease-relevant in vivo models. This article examines the evolving landscape for the integrated assessment of function, encompassing multipotent colony-forming cell assays, single-cell RNA sequencing, advanced proteomic and metabolomic profiling, and novel models to evaluate vessel regeneration through human cell transplantation into immune-deficient mice with T2DM-associated comorbidities. We also highlight promising regenerative strategies using glucose-reducing agents, alongside rigorous omics-driven precision profiling to quantify the recovery of VR cell function during T2DM, underscoring an urgent need to progress beyond phenotypic studies toward functionally integrated models that predict translational efficacy. Article Highlights Vascular regenerative cells, including endothelial precursor cells and hematopoietic progenitor cells, exhibit altered regenerative function in type 2 diabetes. Traditional definitions of endothelial precursor cells lack phenotypic specificity, limiting interpretation of regenerative capacity across studies. Functional assays, including colony formation, migration, and in vivo ischemic models for type 2 diabetes, have revealed defects in angiogenesis, proliferation, and repair. Emerging omics approaches provide mechanistic insight into vascular regenerative cell exhaustion across metabolic and inflammatory states. Standardized phenotyping and functional assays are needed to improve the translational success of regenerative therapies for cardiometabolic diseases.